[DOI] [PubMed] [Google Scholar] Lewis DA, Lieberman JA
The need of the hour is to have more randomized, double-blind, placebo-controlled trials with a larger sample size, long term follow-up period, with well defined primary and secondary outcomes, targeted to evaluate the efficacy and safety of the skin-lightening effects of topical, oral and parenteral glutathione
SLNs have shown potential in the treatment of skin cancer by enhancing the delivery of chemotherapeutic agents directly to cancerous cells [118]
Heaney ML, Gardner JR, Karasavvas N, Golde DW, Scheinberg DA, Smith EA, et al
They are often compounded by pharmacies under the guidance of healthcare providers
Products priced to suggest otherwise are unlikely to be delivering the evidence-backed dose